3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
2
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
5
Stomach Neoplasms
4
HER2-positive Breast Cancer
3
Neoplasms
2
Hematologic Neoplasms
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
HER2-positive Gastric Cancer
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
6
Carboplatin
3
valrubicin
2
Cisplatin
2
vinflunine
1
toripalimab
1
pertuzumab
1
disitamab vedotin
1
cabazitaxel
1
apaziquone
1
XRP6258
1
Watchful Waiting
1
Vinblastine
1
Trastuzumab
1
Transurethral Resection of Bladder
1
Tranexamic Acid
1
Saline Solution
1
RC48 antibody
1
Oncolytic Virotherapy
1
Mitomycin
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Lapatinib
1
Interferons
1
Interferon-alpha
1
Gabapentin
1
Circulating Tumor DNA
1
Celecoxib
1
BCG Vaccine
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Urinary Bladder Neoplasms
×
Trastuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled